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contradict the results of the intention-to-treat 
analysis.
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The editorialists reply: With respect to the 
comments by Schäfer and colleagues: we think 
that further investigation in this area is required, 
albeit with appropriate informed consent. There 
are at least two major unanswered questions. 
First, we do not know whether the results of the 
SERVE-HF trial were influenced by the specific 
adaptive servo-ventilation algorithm for adjust-
ment of positive pressure. An ongoing trial (Effect 
of Adaptive Servo Ventilation on Survival and Hos-
pital Admissions in Heart Failure [ADVENT-HF]; 
ClinicalTrials.gov number, NCT01128816) has 
different inclusion and exclusion criteria (it in-
cludes patients with both obstructive and central 
apneas) and uses a different adaptive servo-venti-
lation device with a less aggressive adjustment of 
positive pressure. The data and safety monitoring 
board for the ADVENT-HF trial has performed 
two interim analyses subsequent to the initial 
notification of the results of the SERVE-HF trial, 
and it has concluded that there are no safety con-
cerns (Bradley TD: personal communication).
Second, we do not know whether the risks 
and benefits of adaptive servo-ventilation are 
different in specific subgroups of patients with 
sleep-disordered breathing and congestive heart 
failure. Thus, we continue to think that further 
investigation of this topic is required.
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A Randomized, Controlled Trial of Total Knee Replacement
To the Editor: In the study reported by Skou 
and colleagues (Oct. 22 issue),1 patients were ex-
cluded if they had symptomatic knee osteoar-
thritis with pain scores higher than 60 mm on a 
visual-analogue scale (on which scores range 
from 0 to 100, with higher scores indicating 
worse pain). We are unclear as to the rationale 
for excluding patients with this level of pain, who 
are commonly seen in orthopedic practice. We 
agree with the conclusion that total knee replace-
ment is superior to the nonsurgical regimen in-
vestigated. However, we are concerned that the 
exclusion of 117 of 244 otherwise eligible patients 
(48%) because of severity of symptoms may have 
led to substantial underestimation of the effect 
sizes of treatments in both groups, especially in 
the surgical group because of potentially in-
creased crossover rates among the more severely 
symptomatic patients.
Reported serious adverse events (stiffness re-
quiring manipulation of the knee while the pa-
tient was under anesthesia and deep venous 
thrombosis requiring anticoagulation) both oc-
curred among 6% of patients in the total-knee-
replacement group. These rates were higher than 
the respective rates (1.3%2 and 1.5%3) reported 
elsewhere for much larger cohorts. The authors 
did not report the time-to-event end points, care 
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protocols (such as prophylaxis against deep ve-
nous thrombosis), and criteria for manipulation 
of the knee while the patient was under anes-
thesia. Collectively, these factors may lead to 
misinterpretation of the complications associat-
ed with total knee replacement.
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The authors reply: We agree with Teuscher 
and Lieberman that our results cannot be gener-
alized to patients with a pain-intensity rating 
higher than 60 mm on a 100-mm visual-ana-
logue scale during the previous week. However, 
at baseline, 42% of the patients reported pain 
higher than 60 mm when asked about worst pain 
during the previous 24 hours, and 22% reported, 
on average, at least severe pain during activities 
of daily living in the previous week. As stated in 
our article, the mean baseline Knee Injury and 
Osteoarthritis Outcome Score pain subscale score 
of 49 (on a scale ranging from 0 to 100, with 
lower scores indicating more severe pain) was 
similar to previously reported scores in studies 
involving cohorts of patients who underwent to-
tal knee replacement.
In our study, patients who had severe knee 
stiffness during the rehabilitation period received 
manipulation of the knee while they were under 
anesthesia. A recent Danish multicenter study 
that included investigators from our department 
showed that among patients who underwent total 
knee replacement, 2.2% required manipulation 
of the knee while they were under anesthesia.1
At admission to the hospital, all patients in 
our study received prophylaxis against deep 
venous thrombosis with 10 mg of rivaroxaban 
orally once daily for 1 to 3 days. Cases of deep 
venous thromboses were diagnosed on day 2, 
day 3, and day 184 after total knee replacement 
(the third case of deep venous thrombosis oc-
curred in a patient after surgery for femoral-neck 
fracture during the follow-up period). Our trial 
was too small to provide reliable rates of adverse 
events associated with total knee replacement.
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Pediatric Outcome after Maternal Cancer Diagnosed  
during Pregnancy
To the Editor: Amant et al. (Nov. 5 issue)1 re-
port on a study of outcomes in children exposed 
in utero to maternal cancer. Despite the impor-
tance of this study, we are concerned about some 
basic methodologic flaws.2
Although this study is presented as a “pro-
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